

**WHAT IS CLAIMED IS:**

1. A method for complexing AHF in a dispersed medium, comprising:
  - a) providing an AHF protein,
  - b) altering the conformational state of said AHF protein to expose hydrophobic domains therein,
  - c) binding a stabilizer to said exposed hydrophobic domains, and
  - d) at least partially reversing said alteration to associate at least a portion of said protein with said stabilizer.
2. The method of claim 1, wherein said altering comprises contacting said protein with at least one of a chemical and physical perturbant.
3. The method of claim 2, wherein said chemical perturbant comprises organic solvent, urea, buffer having an acidic pH, or guanidium hydrochloride.
4. The method of claim 3, wherein said organic solvent comprises methanol, ethanol, glycerol, or ethylene glycol.
5. The method of claim 1, wherein said altering comprises contacting said protein with an ethanol-water mixture of from about 3% to about 80%.
6. The method of claim 2, wherein said physical perturbant comprises a thermal or pressure change.
7. The method of claim 1, wherein said stabilizer comprises liposome.
8. The method of claim 1, wherein said reversing comprises cooling.
9. The method of claim 1, wherein said reversing comprises solvent removal.
10. The method of claim 1, wherein said reversing comprises dialysis.

11. The method of claim 1, wherein said altering comprises unfolding said AHF protein.
12. The method of claim 1, wherein said reversing comprises refolding said AHF protein.
13. The method of claim 1, further comprising coating the surface of the liposome with a hydrophilic polymer.
14. The method of claim 13, wherein the hydrophilic polymer comprises polyethylene glycol.
15. The method of claim 1, wherein said alteration is performed to expose hydrophobic domains in the SI<sub>3</sub> conformational state of the AHF protein.
16. The method of claim 1, wherein above about 70% of said protein is associated with said stabilizer.
17. The method of claim 1, wherein said association comprises encapsulation of at least a portion of said protein by said stabilizer.
18. The method of claim 17, wherein said at least a portion of said protein comprises above about 0.5% of the protein molecule.
19. The method of claim 17, wherein said at least a portion of said protein comprises above about 25% of the protein molecule.
20. A dispersion system-associated AHF protein produced by the method of claim 1.
21. A pharmaceutically effective stabilized AHF dosage wherein greater than about 0.5% of the AHF molecule is encapsulated by a stabilizer.

22. The product of claim 21, wherein above about 25% of the AHF molecule is encapsulated by the stabilizer.
23. The product of claim 21, further comprising a dispersed system medium.
24. The product of claim 21, wherein said stabilizer comprises liposome.
25. The product of claim 21, wherein the association of a specific region of the protein with liposomes alters a therapeutic response of the non-associated protein.
26. The product of claim 25, wherein the therapeutic response is immunogenicity and antigenicity.